Hend Ahmed El-Hadaad1, Hanan Ahmed Wahba. 1. Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt. hend_am@mans.edu.eg
Abstract
BACKGROUND: Despite median survival of less than 6 months, there is a significant proportion of advanced pancreatic cancer patients who progress ongemcitabine that remains fit, and these patients are candidates for second-line treatment. OBJECTIVE: The objective of this study is to evaluate the efficacy and safety of oxaliplatin plus 5-fluorouracil and folinic acid in patients with gemcitabine-pretreated advanced pancreatic cancer. PATIENTS AND METHODS: Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin (85 mg/m(2)) on days 1 and 15 followed by leucovorin (20 mg/m(2)) and 5-fluorouracil (500 mg/m(2)) on days 1, 8, and 15. The cycle was repeated every 3 weeks. RESULTS: The majority of patients (80 %) had locally advanced disease. Median age was 63 years, and 60 % were males. The liver was the most common site of metastasis. Partial response was observed in 2 patients (6.7 %) and stable disease in 6 patients (20 %), while 12 patients progressed (40 %). Improved performance status was reported in 10 patients (33.3 %). The median duration of response was 13 weeks, and median overall survival was 22 weeks. There was no grade 4 toxicity apart from grade 4 neutropenia in 6.6 % of patients. Neutropenia (46.5 %) and neuropathy (43.2 %) were the most common toxicities, while hand-foot syndrome was the least frequent one (20 %). There were no treatment-related deaths. The 6-month survival rate was 30 %. CONCLUSION: This regimen is feasible and active with an acceptable toxicity; however, further investigation in phase III trial is needed.
RCT Entities:
BACKGROUND: Despite median survival of less than 6 months, there is a significant proportion of advanced pancreatic cancerpatients who progress on gemcitabine that remains fit, and these patients are candidates for second-line treatment. OBJECTIVE: The objective of this study is to evaluate the efficacy and safety of oxaliplatin plus 5-fluorouracil and folinic acid in patients with gemcitabine-pretreated advanced pancreatic cancer. PATIENTS AND METHODS: Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin (85 mg/m(2)) on days 1 and 15 followed by leucovorin (20 mg/m(2)) and 5-fluorouracil (500 mg/m(2)) on days 1, 8, and 15. The cycle was repeated every 3 weeks. RESULTS: The majority of patients (80 %) had locally advanced disease. Median age was 63 years, and 60 % were males. The liver was the most common site of metastasis. Partial response was observed in 2 patients (6.7 %) and stable disease in 6 patients (20 %), while 12 patients progressed (40 %). Improved performance status was reported in 10 patients (33.3 %). The median duration of response was 13 weeks, and median overall survival was 22 weeks. There was no grade 4 toxicity apart from grade 4 neutropenia in 6.6 % of patients. Neutropenia (46.5 %) and neuropathy (43.2 %) were the most common toxicities, while hand-foot syndrome was the least frequent one (20 %). There were no treatment-related deaths. The 6-month survival rate was 30 %. CONCLUSION: This regimen is feasible and active with an acceptable toxicity; however, further investigation in phase III trial is needed.
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: S L Cheeseman; S P Joel; J D Chester; G Wilson; J T Dent; F J Richards; M T Seymour Journal: Br J Cancer Date: 2002-08-12 Impact factor: 7.640
Authors: Andrea Bullock; Keith Stuart; Susanna Jacobus; Thomas Abrams; Raymond Wadlow; Michael Goldstein; Rebecca Miksad Journal: J Gastrointest Oncol Date: 2017-12
Authors: Ishan Roy; Kathleen A Boyle; Emily P Vonderhaar; Noah P Zimmerman; Egal Gorse; A Craig Mackinnon; Rosa F Hwang; Janusz Franco-Barraza; Edna Cukierman; Susan Tsai; Douglas B Evans; Michael B Dwinell Journal: Lab Invest Date: 2017-01-16 Impact factor: 5.662
Authors: Thomas J Ettrich; Lukas Perkhofer; Goetz von Wichert; Thomas M Gress; Patrick Michl; Holger F Hebart; Petra Büchner-Steudel; Michael Geissler; Rainer Muche; Bettina Danner; Volker Kächele; Andreas W Berger; Melanie Güthle; Thomas Seufferlein Journal: BMC Cancer Date: 2016-01-15 Impact factor: 4.430